Ricerca avanzata

Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Articoli online first > Minerva Endocrinologica 2015 Dec 23

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

Periodicità: Trimestrale

ISSN 0391-1977

Online ISSN 1827-1634

 

Minerva Endocrinologica 2015 Dec 23

The natural progression and outcomes of adrenal incidentaloma: a systematic review and meta-analysis

Loh H. H. 1, Yee A. 2, Loh H. S. 3, Sukor N. 4, Kamaruddin N. A. 4

1 Faculty of Medicine and Health Sciences, University of Malaysia Sarawak, Malaysia;
2 Department of Psychiatry, University of Malaya Medical Center, Malaysia;
3 Clinical Academic Unit, Family Medicine, Newcastle University Medicine, Malaysia;
4 Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Center, Malaysia

PURPOSE: Long-term outcome of patients with adrenal incidentaloma (AI) is unknown. The aim of this study was to systematically summarize the follow-up and outcome of clinically silent AI who do not undergo surgery.
METHODS: All major databases and medical literature in English-language, published from 1998 to May 2015, were systematically searched for publications on AI. Primary endpoint was hormonal hyper function; secondary endpoints were time from diagnosis to study endpoint and the outcome of adrenalectomy. Meta-analysis was performed using both qualitative and quantitative approach.
RESULTS: A total of 11 publications were included. Total sample size was 1298 patients. Mean follow-up duration was 44.2 months. There were 82 patients confirmed to have subclinical Cushing’s syndrome at diagnosis, with 1.79% new cases at the end of follow up (95% CI, 0.002 to 0.045). Incidence of Cushing’s syndrome was 0.7% (95% CI, 0.001 to 0.013) and pheochromocytoma 0.4% (95% CI, 0.001 to 0.008). The mean tumor size was 2.52cm, with mean increment of 0.03cm to 2.9cm at the end of follow up. About 3% of patients ended up with surgery (95% CI, 0.01 to 0.05) but none were due to primary adrenal malignancy. Time of greatest risk of developing Cushing’s syndrome and pheochromocytoma was between months 36 and 42 (hazard rate 14%), and between months 48 and 54 (hazard rate 7%) respectively.
CONCLUSION: Malignant change in non-functioning AI is rare. The risk of developing overt disease over the follow-up period is low. A less stringent imaging and functional work-up interval can be considered.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina